Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
$0.38
-7.8%		$0.57
$0.38
▼
$3.62
$38.23M1.742.28 million shs3.04 million shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
MDxHealth SA stock logo
MDXH
MDxHealth
$0.72
-0.1%		$0.52
$0.40
▼
$5.33
$35.71M1.4217.68 million shs271,559 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.41
+6.6%		$3.51
$2.04
▼
$16.25
$32.68M1.6359,357 shs333,279 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-7.79%-23.28%-37.81%-86.54%-55.38%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
MDxHealth SA stock logo
MDXH
MDxHealth
-0.11%-3.01%+80.08%-4.29%-79.92%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+6.64%-1.23%-23.49%-47.38%-57.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
$0.38
-7.8%		$0.57
$0.38
▼
$3.62
$38.23M1.742.28 million shs3.04 million shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
MDxHealth SA stock logo
MDXH
MDxHealth
$0.72
-0.1%		$0.52
$0.40
▼
$5.33
$35.71M1.4217.68 million shs271,559 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.41
+6.6%		$3.51
$2.04
▼
$16.25
$32.68M1.6359,357 shs333,279 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-7.79%-23.28%-37.81%-86.54%-55.38%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
MDxHealth SA stock logo
MDXH
MDxHealth
-0.11%-3.01%+80.08%-4.29%-79.92%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+6.64%-1.23%-23.49%-47.38%-57.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
2.70
Moderate Buy$6.171,507.16% Upside
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00
N/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
2.40
Hold$2.17200.63% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00356.43% Upside

Current Analyst Ratings Breakdown

Latest GLYC, CNTX, MDXH, and RADX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
MDxHealth SA stock logo
MDXH
MDxHealth
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$4.00 ➝ $2.00
8/20/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
MDxHealth SA stock logo
MDXH
MDxHealth
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$5.00 ➝ $3.00
8/6/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/6/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/16/2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$8.00 ➝ $4.00
6/4/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/A$0.42 per shareN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,013.15N/AN/A$0.08 per share1.96
MDxHealth SA stock logo
MDXH
MDxHealth
$107.88M0.33N/AN/A($0.61) per share-1.18
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.35M14.83N/AN/A$3.52 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$36.12M-$0.48N/AN/AN/AN/A-82.06%-72.74%11/4/2026 (Estimated)
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/A
MDxHealth SA stock logo
MDXH
MDxHealth
-$33.52M-$0.72N/AN/AN/A-33.46%N/A-24.25%N/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$24.83MN/AN/AN/AN/AN/AN/AN/AN/A

Latest GLYC, CNTX, MDXH, and RADX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
MDxHealth SA stock logo
MDXH
MDxHealth
-$0.1934-$0.18+$0.0134-$0.22$26.14 million$27.21 million
8/5/2026Q2 2026
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$0.0921-$0.15-$0.0579-$0.15N/AN/A
7/31/2026Q4 2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A-$0.81N/A-$0.8050N/A$0.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/A
5.81
5.81
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
MDxHealth SA stock logo
MDXH
MDxHealth
N/A
1.15
0.98
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
3.01
N/A

Institutional Ownership

CompanyInstitutional Ownership
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
14.03%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
MDxHealth SA stock logo
MDXH
MDxHealth
N/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
4.80%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
MDxHealth SA stock logo
MDXH
MDxHealth
1.70%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
791.88 million87.47 millionNot Optionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionNo Data
MDxHealth SA stock logo
MDXH
MDxHealth
30049.50 million48.66 millionNot Optionable
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A14.46 millionN/AN/A

Recent News About These Companies

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
August 26 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351185/0/en/radiopharm-theranostics-doses-first-patient-in-second-cohort-of-phase-1-2a-clinical-trial-of-betabart-rv-01-in-b7-h3-expressing-solid-tumors.html
Radiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's Why
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973662
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-meet-u-fda-113000466.html
RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
Radiopharm Dips on Securities Pact
July 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23725/Radiopharm-Dips-on-Securities-Pact
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332785/0/en/radiopharm-theranostics-announces-concurrent-us-4-1-million-registered-direct-offering-and-up-to-additional-a-12-7-us-8-9-million-australian-placement-and-share-purchase-plan.html
Radiopharm Highlights Data Release
July 23, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5668/Radiopharm-Highlights-Data-Release
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331243/0/en/radiopharm-theranostics-achieves-confirmed-durable-partial-response-in-ongoing-phase-1-trial-of-rad204-in-patients-with-advanced-solid-tumors-post-immunotherapy.html
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331214/0/en/radiopharm-theranostics-announces-positive-phase-2b-trial-results-of-rad-101-for-diagnosis-of-brain-metastases.html
Radiopharm Theranostics Ltd ADR RADX
July 16, 2026  |  morningstar.comM
Radiopharm Theranostics Limited Sponsored ADR
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RADX
RADX: Fiscal 3Q:26 Cash Flow Report
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-fiscal-3q-26-cash-092400408.html
Radiopharm Theranostics Ltd. ADR
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/radx/financials
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
April 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/radiopharm-theranostics-adr-radx-inside-the-clinical-programs-1748993/
Radiopharm Theranostics Reports Business Update
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/radiopharm-theranostics-reports-business-update.html
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radiopharm-theranostics-presents-initial-findings-110000207.html
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-completes-enrollment-in-u-s-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases-1036028670
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-increased-by-752-98-to-39-26/ar-AA20YjrZ
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-decreased-by-1104-to-460/ar-AA20utAZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Context Therapeutics stock logo

Context Therapeutics NASDAQ:CNTX

$0.38 -0.03 (-7.79%)
As of 08/28/2026 04:00 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

MDxHealth stock logo

MDxHealth NASDAQ:MDXH

$0.72 0.00 (-0.11%)
As of 08/28/2026 04:00 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$2.41 +0.15 (+6.64%)
As of 08/28/2026 04:00 PM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas